TRIVARX LTD — Board/Management Information 2026

Mar 4, 2026

ASX ANNOUNCEMENT

==> picture [123 x 44] intentionally omitted <==

5 March 2026

Key management changes

Perth, Australia, and Minneapolis, USA: TrivarX Limited (‘the Company’ ) (ASX: TRI) wishes to provide the following update regarding key personnel changes including the departure of its Chief Medical Officer, enhanced director involvement to support commercialisation and changes to the Company Secretary.

Chief Medical Officer Departure

The Company advises it has terminated the employment of Chief Medical Officer, Dr Archie Defillo, effective 4 March 2026. Dr Defillo has been involved with the Company since 2018 and has been integral to the development of TrivarX’s MEB-001 and single-channel ECG algorithms. The Company would like to thank him for his services and wish him well for future endeavours.

Director Involvement to Support Commercialisation

To advance commercialisation initiatives across both the Company’s mental health and Stabl-Im technologies, the Company will deploy the expertise of seasoned healthcare leaders and existing directors, Dr Tony Keating and Mr Chris Ntoumenopoulos.

Both directors will bring commercialisation expertise from their experience at ResApp Health (previously ASX: RAP). Dr Keating, as co-founder and Chief Executive Officer of ResApp, led the company’s strategic, regulatory and commercial execution, advancing its smartphone-based respiratory diagnostic technology through clinical validation, securing regulatory progress across key jurisdictions and driving global partnership discussions, culminating in its acquisition by Pfizer in 2022 for approximately $180m.

Mr Ntoumenopoulos, as co-founder of ResApp, was instrumental in the company’s strategic direction and governance during its growth and development. He provided strategic guidance as the company progressed its AI-drive diagnostic platform through key corporate, clinical and regulatory milestones, including progress towards FDA clearance, and the company’s eventual acquisition by Pfizer.

Together, they bring proven a proven track record of guiding ASX-listed digital health technologies from development and clinical validation through regulatory advancement and strategic value realisation.

Separately, the Company has been advancing a dedicated recruitment search for a Chief Scientific Officer (CSO) to further strengthen its clinical and regulatory leadership as it advances commercialisation of its technology platforms.

Change in Company Secretary

Further, the Company advises that Mr Stephen Buckley has resigned as Company Secretary, effective 1 April 2026. With effect from that date, Mr Cameron Jones and Ms Nova Taylor have been appointed as Joint Company Secretaries.

Mr Jones is the Founding and Managing Director of Bio101. A qualified Chartered Accountant and registered tax agent, Cameron acts as CFO, Company Secretary and transaction advisor for a number of ASX listed and Venture Capital investee companies. Cameron has assisted a number of companies through the Initial Public Offering (IPO) process, capital raisings and M&A transactions.

Cameron holds a Bachelor of Business from Monash University, majoring in Accounting, a Diploma in Financial Planning from Kaplan Professional, registered tax agent and a Certificate in Governance Practice from the Governance Institute of Australia.

TrivarX Limited (A.B.N. 58 008 130 336) 647 Beaufort Street, Mount Lawley, WA 6050

ASX ANNOUNCEMENT

==> picture [123 x 44] intentionally omitted <==

Ms Taylor is a professional Company Secretary with approximately 9 years’ experience working with ASX listed companies across multiple industries. Nova holds a Bachelor Science and Bachelor of Laws from Deakin University.

Mr Jones and Ms Taylor will be responsible for communications with ASX in relation to Listing Rule matters under ASX Listing Rule 12.6.

Commentary

Non-executive Chairman, David Trimboli said: “On behalf of the Board, I would like to thank Dr Defillo for his contribution to the Company’s clinical and algorithm development over recent years.

As we transition toward a more commercially focused phase for both our mental health pipeline and Stabl-Im technology, we are fortunate to have directors with direct experience in scaling and exiting ASX-listed healthcare technology businesses. Tony and Chris bring deep expertise in regulatory strategy, commercial execution, capital markets and global partnering, which will be critical as we advance our next stage of growth.

I would also like to thank Stephen Buckley for his service to the Company and welcome Cameron and Nova to the Company Secretary role. Cameron brings significant governance, financial and ASX-listed healthcare sector experience, and his appointment further strengthens the Company’s corporate and compliance framework as we continue to execute our strategy.

The Board remains confident in the Company’s direction and is focused on progressing commercial pathways and delivering long-term value for shareholders.”

Change in Director remuneration

The Company further advises that it has updated its director remuneration arrangements

• Christopher Ntoumenopoulos – Non-Executive Director Effective immediately, Non-Executive Director remuneration payable to Mr Christopher Ntoumenopoulos will comprise $60,000 per annum for Non-Executive Director fees and an additional $40,000 per annum for the provision of strategic advisory services relating to the Company’s commercialisation strategy, partnership development and broader business development activities associated with both its mental health and Stabl-Im technology suite, inclusive of superannuation and will be paid entirely in cash, replacing the prior equity-based fee arrangement.

• Tony Keating – Non-Executive Director

• Effective immediately, Non-Executive Director remuneration payable to Mr Tony Keating will comprise $60,000 per annum for Non-Executive Director fees and an additional $40,000 per annum for the provision of services relating to regulatory strategy, clinical development planning and broader program advancement, inclusive of superannuation and will be paid entirely in cash, replacing the prior equity-based fee arrangement.

• David Trimboli – Non-Executive Chair -

• Effective immediately, Non Executive Chair remuneration payable to Mr David Trimboli will comprise $100,000 per annum (inclusive of superannuation) and will be paid entirely in equity.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

TrivarX Limited (A.B.N. 58 008 130 336) 647 Beaufort Street, Mount Lawley, WA 6050

ASX ANNOUNCEMENT

==> picture [123 x 44] intentionally omitted <==

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations Henry.jordan@sdir.com.au +61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au

TrivarX Limited (A.B.N. 58 008 130 336) 647 Beaufort Street, Mount Lawley, WA 6050